Travere Therapeutics, Inc.

NASDAQ:TVTX

17.57 (USD) • At close November 1, 2024
Bedrijfsnaam Travere Therapeutics, Inc.
Symbool TVTX
Munteenheid USD
Prijs 17.57
Beurswaarde 1,343,955,655
Dividendpercentage 0%
52-weken bereik 5.12 - 19.25
Industrie Biotechnology
Sector Healthcare
CEO Dr. Eric M. Dube Ph.D.
Website https://www.travere.com

An error occurred while fetching data.

Over Travere Therapeutics, Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric

Vergelijkbare Aandelen

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

41.69 USD

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

176.39 USD

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

5.28 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

45.42 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

126.27 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

110.04 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

11.78 USD

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

33.97 USD

ModivCare Inc. logo

ModivCare Inc.

MODV

16.18 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)